← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Net income increased 198.9% to $53.4M, while Operating cash flow decreased 97.8% to ($44.8M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AOK
- Profitability — Net income $53.4MOK
- Cash generation — Free cash flow ($46.7M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 14 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Business
ELUTIA INC.: "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report and in our other filings with the Securities and Exchange Commission (the "SEC"), each of which filings are accessible on the SEC's website at www.sec.gov and the Investor Relations page of our website at https://investors.Elutia.com/financials/sec-filings. Moreover, we operate in an evolving environment.
Where the revenue comes from
Fiscal 2025, as ELUTIA INC. reports it. History and quarterly detail are in the app.
- Women S Health$9.1M
- Cardiovascular$3.2M
Leadership changes
From ELUTIA INC.'s own filings, the day they're filed.
- Guido Neels · Director · appointmenteff. 2025-10-09
- W. Matthew Zuga · Director · departureeff. 2025-10-08
Latest filings
- 8-K · Company announcement2026-08-21
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-07-20
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ELUTIA INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.